New Study from StrategyR Highlights a $1.7 Billion Global Market for Biometric Sensors by 2026
A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Biometric Sensors - Global Market Trajectory & Analytics". The report presents fresh perspectives on opportunities and challenges in a significantly transformed post COVID-19 marketplace.
FACTS AT A GLANCE
Edition: 9; Released: April 2021
Executive Pool: 1157
Companies: 11 - Players covered include 3M Company; Crossmatch Technologies; Fulcrum Biometrics LLC; Idex Asa; Infineon Technologies AG; NEC Corporation; Precise Biometrics AB; Safran; Suprema, Inc.; ZKTeco USA and Others.
Coverage: All major geographies and key segments
Segments: Application (Voice Scan, Finger Scan, Facial Scan, Iris Scan, Vein Scan, Other Applications); End-Use (Defense, Hospital, Commercial Centers, BFSI, Other End-Uses); Product Type (Capacitive Sensors, Optical Sensors, Thermal Sensors, Other Sensors)
Geographies: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Adlai Nortye, a global biopharmaceutical company focused on developing innovative oncology drugs, today announced that the first patient has been dosed in the Phase Ia clinical trial in the U.S. to evaluate the triple combination of AN2025 (buparlisib, oral pan-PI3K inhibitor), AN0025 (oral EP4 antagonist) and atezolizumab (PD-L1 inhibitor) in patients with locally advanced/metastatic tumors.
This trial (AN2025S0101) is an open-label, multicenter, Phase Ia study to evaluate the safety, tolerability, pharmacokinetics ("PK") and preliminary efficacy of AN2025 and AN0025 in double or triple combination treatments with atezolizumab in patients with locally advanced/metastatic tumors. The study consists of three dose-limiting toxicity ("DLT") Observation Periods, Observation I, II and III. Observations I and II are double combination treatments, which will be conducted in parallel, whereas Observation III (the triple combination treatment) will be initiated only after a thorough review of the safety data from Observations I and II. Each Observation period will last 3 weeks. This study plans to recruit approximately 63 patients. The first patient was dosed at Florida Cancer Specialists - Lake Mary Cancer Center, while the study is also going to recruit patients from the University of Colorado Cancer Center, Rutgers Cancer Institute of New Jersey and Stephenson Cancer Center in Oklahoma.
AN2025 targets not only PI3K mediated tumorigenesis (e.g. via inhibition of PI3Kα/PIK3CA mutants) but also the immunosuppression of the tumor microenvironment (e.g. via inhibition of PI3Kδ and PI3Kγ). According to the Frost & Sullivan Report, PIK3CA alterations are found in approximately 13% of all solid tumors globally, including 25% to 40% of cervical cancer, 30% to 40% of breast cancer, 30% to 35% of endometrial cancer, 30% of ovarian cancer, 24% of urothelial cancer, 20% of colorectal cancer and 10% to 20% of head and neck squamous cell carcinoma ("HNSCC") globally. The global incidence of PIK3CA mutant solid tumors reached approximately 2.3 million in 2020 and is expected to reach approximately 2.9 million in 2030, indicating a substantial overall addressable market and significant commercial potential.
Adlai Nortye aspires to develop differentiated cancer immunotherapy medicines for global markets. The Company's Cocktail therapy strategy represents the third wave of immuno-oncology therapy, featuring the combination of an immune checkpoint inhibitor with two or more additional cancer therapies. The Company expects it to achieve significantly higher overall response rates than present combination therapies. The triple combination of AN2025 (targeted therapy), AN0025 (immuno-oncology therapy) and atezolizumab (immuno-oncology therapy) exemplifies the cocktail therapy strategy of Adlai Nortye.
"Results from preclinical studies of the triple combination of AN2025, AN0025 and an anti-PD1 antibody have demonstrated encouraging antitumor activity. We believe that this triple combination potentially could develop into a novel anti-cancer immune therapy by e...
(All Rights Reserved)